Email Updates

Search form

You are here

HIV Vaccine

There is momentum and promise in the search for an HIV vaccine.

An effective preventive HIV vaccine would teach the body how to prevent HIV infection. Vaccines are the most powerful public health tools available—and an HIV vaccine would play a powerful role in ensuring the end to the AIDS epidemic.

While effective vaccines remain years away, there are more reasons for hope than ever before. Researchers are expanding on the result of a 2009 trial that showed, for the first time, that a vaccine can reduce the risk of HIV infection. They’re also pursuing groundbreaking research with other novel vaccine strategies, including broadly neutralizing antibodies that target a wide range of HIV strains. At the same time, there is also exciting work in efforts to understand if and how to cure HIV in people who are already infected. The timeline for this work is long and uncertain. Here, too, advocacy is needed to sustain momentum.

Today’s momentum depends on sustained funding. Policy makers and funders around the world must have the courage to sustain vital HIV vaccine research for years to come, and advocates must keep the pressure on them to maintain their commitments.

What We're Reading

A handy Q&A provided by National Institute of Allergy and Infectious Disease (NIAID) explores some of the important details of the first large-scale, advanced-stage vaccine study since 2009.

November 27, 2016
NIH

Bhekisisa Center for Health Journalism has this article out explaining two major initiatives advancing vaccine research: the HVTN 702 study building on the work of the 2009 Thai Trial, and another using laboratory-made broadly neutralising antibodies to beef up immune response to HIV. Both studies are being conducted in South Africa and represent the frontier in vaccine research in 2016.

November 24, 2016
Bhekisisa
Subscribe to RSS - HIV Vaccine